N
Nicola Maayan
Researcher at Cochrane Collaboration
Publications - 33
Citations - 2234
Nicola Maayan is an academic researcher from Cochrane Collaboration. The author has contributed to research in topics: Randomized controlled trial & Relative risk. The author has an hindex of 18, co-authored 33 publications receiving 1954 citations.
Papers
More filters
Journal ArticleDOI
Memantine for dementia
Rupert McShane,Maggie J Westby,Emmert Roberts,Neda Minakaran,Lon S. Schneider,Lucy Farrimond,Nicola Maayan,Jennifer Ware,Jean Debarros +8 more
TL;DR: A small beneficial effect of memantine at six months in moderate to severe AD is suggested and the statistical significance of these benefits could be overturned by data from two unpublished studies which are known to show no significant effect.
Journal ArticleDOI
Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
TL;DR: The effects of giving deworming drugs to children to treat soil‐transmitted helminths on weight, haemoglobin, and cognition; and the evidence of impact on physical well‐being, school attendance, school performance, and mortality are summarized.
Journal ArticleDOI
Respite care for people with dementia and their carers
TL;DR: Current evidence does not demonstrate any benefits or adverse effects from the use of respite care for people with dementia or their caregivers, and well-designed trials are needed in this area.
Journal ArticleDOI
Vitamin E for neuroleptic-induced tardive dyskinesia.
TL;DR: Small trials with uncertain quality of randomisation, tend to suggest that vitamin E improves the symptoms of TD and methodological problems such as small sample size, short term interventions, and inappropriate use of crossover design need to be dealt with.
Journal ArticleDOI
Aromatherapy for dementia
Lene Thorgrimsen Forrester,Nicola Maayan,Martin Orrell,Aimee Spector,Louise D Buchan,Karla Soares-Weiser +5 more
TL;DR: The benefits of aromatherapy for people with dementia are equivocal from the seven trials included in this review, and several issues need to be addressed, such as whether different aromather therapy interventions are comparable and the possibility that outcomes may vary for different types of dementia.